Rivastigmine is both a pseudo-irreversible acetylcholinesterase inhibitor (AChEI) and a butyrylcholinesterase inhibitor (BuChE I), effective in the symptomatic treatment of mild to moderate dementia in AD and Parkinson’s disease (PD) [32,33,34]. This evidence concerns the gene BCHE and Parkinson disease.